A Comparative Trial of the Diagnostic Quality of Metrizamide 180 mg/ml and 280 mg/ml for Leg Phlebography

Abstract

SUMMARY Metrizamide represents a significant advance in patient tolerance to ascending phlebography of the leg. The objection to its general introduction is its high cost. From a randomised, prospective, within patient study using metrizamide 280mg/ml for one leg and 180mg/ml for the other, it is concluded that a substantial reduction in cost can be made using the more dilute medium while maintaining full diagnostic quality.